Top Stock Reports for Amgen, Eaton & Enzo Biochem

Zacks12-05

Wednesday, December 4, 2024 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489124551?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28","is_english":true,"pubTime":"2024-12-05 05:28","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2489124551","market":"us","top_or_hot":-1,"title":"Top Stock Reports for Amgen, Eaton & Enzo Biochem","media":"Zacks","content":"<div>\n<p>Wednesday, December 4, 2024\nThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc...</p>\n\n<a href=\"https://finance.yahoo.com/news/top-stock-reports-amgen-eaton-212800944.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Stock Reports for Amgen, Eaton & Enzo Biochem</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Stock Reports for Amgen, Eaton & Enzo Biochem\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-05 05:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/top-stock-reports-amgen-eaton-212800944.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wednesday, December 4, 2024\nThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc...</p>\n\n<a href=\"https://finance.yahoo.com/news/top-stock-reports-amgen-eaton-212800944.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999017495.SGD","symbol_name":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/top-stock-reports-amgen-eaton-212800944.html","article_id":"2489124551","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489124551","pubTimestamp":1733347680,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Amgen’s shares have underperformed the Zacks Medical – Biomedical and Geneticsindustry over the last six months . The Zacks analyst believes that increased pricing headwinds and competitive pressure are hurting sales of many products, including some biosimilars. Weakness in some key brands like Otezla and Lumakras pose potential threat.However, Evenity, Repatha, Prolia, Tavneos and Tezspire, are driving sales exponentially. The addition of Horizon products boosted revenue growth in the first half of the year. Amgen also has some key pipeline assets in obesity and inflammation, which have a large market opportunity.However, Sony’s performance is affected by reduced hardware sales, forex volatility and intense competition across major product categories. Continued slowdown across the financial services business and lower series deliveries in Television Productions have also ailed.Moving iMage’s shares have underperformed the Zacks Technology Services industry over the last six months . T","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","EVER":"Everquote Inc.","GD":"通用动力","AMGN":"安进","ICLR":"ICON plc","LU0476273544.USD":"CT (LUX) I GLOBAL TECHNOLOGY \"BU\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","GMED":"Globus Medical Inc","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","MITQ":"Moving iMage Technologies Inc.","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","LU1983260115.SGD":"Janus Henderson Horizon Global Sustainable Equity A2 SGD-H","META":"Meta Platforms, Inc.","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","FDS":"辉盛研究系统","ETN":"伊顿","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4566":"资本集团","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1043141123.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) INC 2","IE00B775H168.HKD":"JANUS HENDERSON BALANCED \"A5M\" (HKD) INC","LU1992135472.HKD":"ALLIANZ GLOBAL INTELLIGENT CITIES \"AT\" (HKD) ACC","ZBRA":"斑马技术","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","BK4141":"半导体产品","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","ENZ":"恩佐生化","NXPI":"恩智浦","BK4561":"索罗斯持仓","LU0157215616.USD":"FIDELITY GLOBAL FOCUS \"A\" INC","ESS":"埃塞克斯信托","IP":"国际纸业","SEM":"Select Medical Holdings","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","WSM":"Williams-Sonoma Inc","BK4096":"电气部件与设备","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","SONY":"索尼","MPC":"马拉松原油","MO":"奥驰亚"},"translate_title":"安进、伊顿和恩佐生物化学的热门股票报告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBRA":1,"AMGN":1,"META":1,"MITQ":1,"IP":1,"MO":1,"MPC":1,"NXPI":1,"SEM":1,"ICLR":1,"GMED":1,"FDS":1,"EVER":1,"ETN":1,"ESS":1,"ENZ":1,"GD":1,"SONY":1,"WSM":1},"content_text":"Wednesday, December 4, 2024\nThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), Eaton Corp. plc (ETN) and Sony Group Corp. (SONY), as well as two micro-cap stocks, Moving iMage Technologies, Inc. (MITQ) and Enzo Biochem, Inc. (ENZ). These research reports have been hand-picked from roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>\nAmgen’s shares have underperformed the Zacks Medical – Biomedical and Genetics industry over the last six months (-9.4% vs. -2.0%). The Zacks analyst believes that increased pricing headwinds and competitive pressure are hurting sales of many products, including some biosimilars. Weakness in some key brands like Otezla and Lumakras pose potential threat.\nHowever, Evenity, Repatha, Prolia, Tavneos and Tezspire, are driving sales exponentially. The addition of Horizon products boosted revenue growth in the first half of the year. Amgen also has some key pipeline assets in obesity and inflammation, which have a large market opportunity.\n(You can read the full research report on Amgen here >>>)\nEaton’s shares have outperformed the Zacks Manufacturing - Electronics industry over the past year (+65.7% vs. +33.9%). The Zacks analyst believes that the company benefits from research and development work and is aided by rising demand from the new AI data center. Eaton is expanding via acquisitions and strategy to manufacture in the region of its end market has helped the company to reduce expenses.\nYet, Eaton’s global operations expose it to unpredictable currency translation, cyber security threats, changes in tax rates and security breaches, which might impact operations. The shortage of raw materials and supplier insolvencies might impact production and operations.\n(You can read the full research report on Eaton here >>>)\nShares of Sony have outperformed the Zacks  Audio Video Production industry over the past year (+18.4% vs. +13.0%). Per the Zacks analyst, steady growth across the G&NS, Music and I&SS segments has been a tailwind for Sony. The G&NS unit is gaining from favorable forex impact, higher sales from network services (PlayStation Plus) and rising sales of non-first-party titles.\nHowever, Sony’s performance is affected by reduced hardware sales, forex volatility and intense competition across major product categories. Continued slowdown across the financial services business and lower series deliveries in Television Productions have also ailed.\n(You can read the full research report on Sony here >>>)\nMoving iMage’s shares have underperformed the Zacks Technology Services industry over the last six months (-35.5% vs. +43.7%). The Zacks analyst believes that supply chain disruptions, competition from OTT platforms and regulatory compliance costs have continued to ail the company. Hollywood strikes earlier this year impacted demand for its products.\nYet, its significant contract win with Alamo Drafthouse Cinema and expansion into high-margin SaaS and subscription-based products like MiTranslator and CineQC show great promise. Also, diversifying into live entertainment and eSports markets mitigates cinema industry cyclicality.\n(You can read the full research report on Moving iMage here >>>)\nEnzo’s shares have underperformed the Zacks Medical – Biomedical and Genetics industry over the past year (-13.7% vs. +1.0%). The Zacks analyst believes that persistent net losses, high operating costs, the exit from clinical labs reducing revenue streams and competitive pressures pose risks for the company. Addressing legal expenses are also crucial for sustained profitability.\nYet, Enzo’s strategic pivot toward becoming a dedicated life sciences tools manufacturer has been effectively executed and is a major plus. Its broad and deep intellectual property (IP) portfolio, with patent coverage across vital enabling technologies also positions the company as a leader in innovation.\n(You can read the full research report on Enzo here >>>)\nOther noteworthy reports we are featuring today include Meta Platforms, Inc. (META), Altria Group, Inc. (MO) and General Dynamics Corp. (GD).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>\nToday's Must Read\nAmgen (AMGN) Well-Poised for Growth on a Solid Pipeline\nNew Product Development, Wide Market Reach Aid Eaton (ETN)\nHigher Music & G&NS Sales Aid SONY Amid Soft Hardware Sales\nFeatured Reports\nUser Growth, Instagram Strength Aids Meta Platforms (META)Per the Zacks analyst, Meta Platforms is benefiting from a strengthening user base. Improving engagement level for Instagram, Messenger and WhatsApp bode well.\nMarathon (MPC) to Gain from Sale of Speedway Retail UnitThe Zacks analyst likes Marathon's sale of Speedway business and the resulting cash infusion but is worried over the execution risk associated with its foray into renewable diesel activities.\nRental Unit Demand Aid Essex Property (ESS) Amid High SupplyPer the Zacks Analyst, Essex Property is likely to gain from the healthy renter demand amid high home ownership costs. However, an elevated supply of apartment units in some of its market ails.\nFactSet (FDS) Gains From Idacti Buyout, Competition High Per the Zacks analyst, the Idacti acquisition supports FactSet's ongoing initiative to digitally revamp its content collection infrastructure. Rising competition from other players is an overhang.\nGeneral Dynamics (GD) Gains From Orders, Amid Supply IssuesAs per the Zacks analyst, General Dynamics is likely to benefit from increasing defense order growth from the Pentagon and U.S. allies. Yet, supply chain issues result in product delivery delays.\nAltria (MO) Benefits From Strategic Pricing Initiatives Per the Zacks analyst, Altria is benefiting from robust pricing actions. During third-quarter 2024, higher pricing strategies aided revenues across the Smokeable Products and Oral Tobacco categories.\nStrategic Plans Aid Williams-Sonoma (WSM), High Costs HurtPer the Zacks analyst, Williams-Sonoma gains from return to growth strategy, which reflects focus on innovation, improving channel experiences and customer service. Yet, high costs and expenses ail.\nNew Upgrades\nEverQuote (EVER) Boasts Revenue Growth, Solid Balance SheetPer the Zacks analyst, consumer traffic, quote request volume and innovative advertiser products and services drive EverQuote revenues. Its strong balance sheet enables it to fulfill debt obligations.\nMusculoskeletal Solutions Products Aid Globus Medical (GMED)The Zacks analyst is impressed with Globus Medical's rising market share in the musculoskeletal solutions space, driven by gains across its product portfolio in expandables, and 3D printed implants.\nEnterprise Visibility Unit Aids Zebra Technologies (ZBRA)Per the Zacks analyst, Zebra Technologies' Enterprise Visibility and Mobility segment is benefiting from solid demand for mobile computing products, data capture solutions and services and software.\nNew Downgrades\nEscalating Costs, High Debt Level Hurts Select Medical (SEM)Per the Zacks analyst, a rise in Select Medical's expenses due to the higher cost of services might dent the company's margins. Its high leverage remains a concern.\nSluggish Biotech Recovery Ails ICON (ICLR), FX Woes StayThe Zacks analyst is worried about ICON's Biotech arm witnessing slower decision-making and capital allocation, leading to award delays and slow trial starts. Adverse FX impacts add to the concerns. \nNXP Semiconductors (NXPI) Hurt by Sluggish Automotive MarketPer the Zacks analyst, NXP Semiconductors is suffering from softness in the automotive end-market, owing to increased inventory corrections by direct Tier 1 customers.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nGeneral Dynamics Corporation (GD) : Free Stock Analysis Report\nAmgen Inc. (AMGN) : Free Stock Analysis Report\nEaton Corporation, PLC (ETN) : Free Stock Analysis Report\nAltria Group, Inc. (MO) : Free Stock Analysis Report\nSony Corporation (SONY) : Free Stock Analysis Report\nMeta Platforms, Inc. (META) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489124551"}